---
title: Slow Parkinson degeneration using Dserine
nct_id: NCT07312110
phase: PHASE2
status: RECRUITING
sponsor: Haukeland University Hospital
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT07312110"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07312110"
last_fetched: "2026-05-10T14:03:03.516Z"
source: "Parkinson's Pathways (curated)"
---
# Slow Parkinson degeneration using Dserine

**Goal (in five words):** Slow Parkinson degeneration using Dserine

**Official Title:** D-SPARK: A Randomized Double Blind Clinical Trial of D-Serine for Modifying Parkinson's Disease Progression

**Trial ID:** [NCT07312110](https://clinicaltrials.gov/study/NCT07312110)

## Key Facts

- **Phase:** PHASE2
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** Haukeland University Hospital
- **Target Enrollment:** 100 participants
- **Start Date:** 2026-01
- **Completion Date:** 2028-03
- **Conditions:** Parkinson s Disease, Parkinson Disease (PD)
- **Interventions:** D-serine, Placebo
- **Intervention Types:** DIETARY_SUPPLEMENT

## Summary For Families

The goal is to find out whether D-serine can slow Parkinson's progression by boosting glutamate-driven synaptic function and helping protect neurons, not just treating symptoms. D-serine is a natural co-agonist at NMDA receptors, it enhances NMDA receptor signaling to support synaptic plasticity and neuronal health, and it will be tested against placebo while participants stay on stable Parkinson's meds. The trial seeks people 40 to 80 years old diagnosed within the last 5 years with DaTscan-confirmed PD and Hoehn and Yahr under 3, on stable symptomatic treatment; dementia, atypical parkinsonism, significant kidney disease, recent D-serine use, and other serious medical or psychiatric issues are exclusions.

## Eligibility

- **Minimum age:** 40 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* A clinical diagnosis of PD\* according to the clinically established MDS clinical diagnostic criteria for Parkinson's disease within 5 years.
* \[¹²³I\]FP-CIT single photon emission CT (DaTscan) confirming dopaminergic nigrostriatal denervation.
* Hoehn and Yahr score \< 3 at enrollment.
* Optimal symptomatic PD treatment, not requiring adjustments, for at least 2 weeks.
* Age ≥40 and ≤ 80 years at time of enrollment.

Exclusion Criteria:

* Dementia or neurodegenerative disorder other than PD at baseline visit.
* Atypical parkinsonism (PSP, MSA, CBD vascular parkinsonism, or drug induced parkinsonism).
* Any known monogenic cause of PD (GBA1 variation is accepted).
* Any psychiatric disorder that would interfere with compliance in the study.
* Any severe somatic illness that would make the individual unable to comply and participate in the study.
* Use of D-serine supplementation within 90 days of enrolment.
* Metabolic, neoplastic, or other physically or mentally debilitating disorder at baseline visit.
* Active of planned pregnancy during trial period.
* Cognitive impairment as measured by the Mini Mental Status Exam MMSE) \< 20.
* Weight \< 45 kg.
* Urinary albumin/creatinine ratio ≥ 20 mg/mmol at time of enrollment.
* Participants will be excluded if they have CKD stage 3 or higher, defined as:

  * Estimated golumerular filtration rate (eGFR) \< 60 mL/min/1.73min\^2 at screening, calculated using the CKD-EPI 2021 creatinine equation.
```

## Locations (11)

- Sørlandet Hospital Arendal, Arendal, Agder, Norway _(58.4615, 8.7725)_
  - Karen Herlofson, MD, PhD — (CONTACT) — Karen.Herlofson@sshf.no
  - Karen Herlofson, MD, PhD — (PRINCIPAL_INVESTIGATOR)
- Akershus University Hospital, Lørenskog, Akershus, Norway
  - Krisztina Kunszt Johansen, MD, PhD — (CONTACT) — krisztina.johansen@ahus.no
  - Krisztina Kunszt Johansen, MD, PhD — (PRINCIPAL_INVESTIGATOR)
- Vestre Viken Hospital, Drammen, Buskerud, Norway _(59.7439, 10.2045)_
  - Kari Anne Bjørnarå, MD, PhD — (CONTACT) — kari.anne.bjornara@vestreviken.no
  - Kari Anne Bjørnarå, MD, PhD — (PRINCIPAL_INVESTIGATOR)
- Molde Hospital, Molde, Møre og Romsdal, Norway _(62.7375, 7.1591)_
  - Eldbjørg Hustad, MD, PhD — (CONTACT) — Eldbjorg.Hustad@helse-mr.no
  - Eldbjørg Hustad, MD, PhD — (PRINCIPAL_INVESTIGATOR)
- Bodø Hospital (Nordland Hospital), Bodø, Nordland, Norway _(67.2827, 14.3751)_
  - Espen Benjaminsen, MD, PhD — (CONTACT) — Epen.benjaminsen@nordlandssykehuset.no
  - Espen Benjaminsen, MD, PhD — (PRINCIPAL_INVESTIGATOR)
- Oslo University Hospital, Oslo, Oslo, Norway _(59.9127, 10.7461)_
  - Lasse Pihlstrøm, MD, PhD — (CONTACT) — lasse.pihlstrom@medisin.uio.no
  - Lasse Pihlstrøm, MD, PhD — (PRINCIPAL_INVESTIGATOR)
- Haugesund Hospital, Haugesund, Rogaland, Norway _(59.4138, 5.2680)_
  - Roelfien Ida HøgenEsch, MD, PhD — (CONTACT) — roelfien.ida.hogenesch@helse-fonna.no
  - Roelfien Ida HøgenEsch, MD, PhD — (PRINCIPAL_INVESTIGATOR)
- University Hospital of North Norway, Tromsø, Troms, Norway _(69.6489, 18.9551)_
  - Hallvard Lilleng, MD, PhD — (CONTACT) — Hallvard.Lilleng@unn.no
  - Hallvard Lilleng, MD, PhD — (PRINCIPAL_INVESTIGATOR)
- Haukeland University Hospital, Bergen, Vestland, Norway _(60.3930, 5.3242)_
  - Charalampos Tzoulis, MD, PhD — (CONTACT) — 55975061 — charalampos.tzoulis@helse-bergen.no
  - Haakon Berven, MD — (CONTACT) — 55755045 — haakon.berven@helse-bergen.no
  - Haakon Berven, MD — (PRINCIPAL_INVESTIGATOR)
  - Geir Olve Skeie, MD, PhD — (PRINCIPAL_INVESTIGATOR)
- Førde Hospital, Førde, Vestland, Norway _(61.4522, 5.8572)_
  - Aliaksei Labusau, MD, PhD — (CONTACT) — aliaksei.labusau@helse-forde.no
  - Aliaksei Labusau, MD, PhD — (PRINCIPAL_INVESTIGATOR)
- Østfold Hospital, Sarpsborg, Østfold fylke, Norway _(59.2839, 11.1096)_
  - Gabriela Fortes, MD — (CONTACT) — Gabriela.Fortes@so-hf.no
  - Gabriela Fortes, MD — (PRINCIPAL_INVESTIGATOR)

## Central Contacts

- Charalampos Tzoulis, MD, PhD — (CONTACT) — 55975061 — charalampos.tzoulis@helse-bergen.no
- Haakon Berven, MD — (CONTACT) — 55975045 — haakon.berven@helse-bergen.no

---

*Canonical: https://parkinsonspathways.com/trial/NCT07312110*  
*HTML version: https://parkinsonspathways.com/trial/NCT07312110*  
*Source data: https://clinicaltrials.gov/study/NCT07312110*